Clinical Trial Update: Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database

View source ↗

Summary

Analysis of real-world outcomes after bowel resection shows differences between patients treated with alvimopan and those not treated with alvimopan, using the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ileus

Drugs mentioned

• Entereg (alvimopan)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Ileus | Status: COMPLETED | Results posted: 2010-09-08